

Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment

Andrea Mohr^{1*}, Laura Deedigan², Sylwia Jencz¹, Yasamin Mehrabadi¹, Lily Houlden^{1,3}, Stella-Maris Albarenque², Ralf M. Zwacka^{1*}

¹School of Biological Sciences, Cancer and Stem Cell Biology Group, University of Essex, Colchester, CO4 3SQ, UK

²National Centre for Biomedical Engineering Science, National University of Ireland Galway, Galway, Ireland

³School of Biosciences and Medicine, University of Surrey, Guildford, GU2 7XH, UK

*correspondence: rzwacka@essex.ac.uk

Ralf Michael Zwacka
University of Essex
School of Biological Sciences
Cancer and Stem Cell Biology Group
Colchester
Essex CO4 3SQ
United Kingdom

Running title: Caspase-10 in cancer treatment responses

Abstract

The mechanisms of how chemotherapeutic drugs lead to cell cycle checkpoint regulation and DNA damage repair are well understood, but how such signals are transmitted to the cellular apoptosis machinery is less clear. We identified a novel apoptosis-inducing complex, we termed FADDosome, which is driven by ATR-dependent caspase-10 upregulation. During FADDosome-induced apoptosis, cFLIP_L is ubiquitinated by TRAF2, leading to its degradation and subsequent FADD-dependent caspase-8 activation. Cancer cells lacking caspase-10, TRAF2 or ATR switch from this cell-autonomous suicide to a more effective, autocrine/paracrine mode of apoptosis initiated by a different complex, the FLIPosome. It leads to processing of cFLIP_L to cFLIP_{p43}, TNF- α production and consequently, contrary to the FADDosome, p53-independent apoptosis. Thus, targeting the molecular levers that switch between these mechanisms can increase efficacy of treatment and overcome resistance in cancer cells.

Introduction

Anti-tumour drugs exert their effect by inducing programmed cell death ¹. Apoptosis can be initiated by various stimuli and factors including growth factor withdrawal, UV, γ -irradiation, signalling by death receptors or chemotherapeutic drugs ² and has been broadly separated into two distinct processes: (a) signal-mediated apoptosis, also known as extrinsic cell death triggered by binding of death ligands such as FasL/CD95L or TRAIL to their cognate receptors ³ and (b) cell death caused by intracellular stress, as for instance initiated by cytotoxic drugs, also known as the intrinsic pathway that typically uses caspase-9 as the initiator caspase ^{4 5 6}. However, there is also ample evidence for the existence and function of other initiator caspase activities upstream of mitochondria in stress- and drug-induced cell death ^{7, 8, 9, 10}.

Recently, apoptosis induction mechanisms involving caspase-8 have been discovered in connection with compounds that block inhibitor-of-apoptosis-proteins (IAPs). Treatment with such compounds resulted in proteasomal degradation of cIAP1, cIAP2 and XIAP leading to NF- κ B activation, upregulation of TNF- α production and subsequent autocrine TNFR1- and caspase-8-mediated apoptosis ^{11, 12, 13, 14, 15}. Later, the topoisomerase II inhibitor Etoposide, which gives rise to DNA double strand breaks, was shown to cause apoptosis through a seemingly similar mechanism in HeLa cells ¹⁶. Additionally, it was shown that IAP inhibition either alone or in combination with Etoposide gives rise to an apoptosis-inducing, RIP1-dependent complex termed RIPoptosome ^{14, 15}. However, Etoposide was previously reported to engage the classic caspase-9-mediated pathway ^{17, 18}. In view of these controversial data, it appears that aside from the canonical caspase-9 pathway several other, possibly cell-type specific, cytotoxic drug-triggered apoptosis-induction mechanisms exist. Furthermore, it remains elusive how the cellular damage caused by these drugs is sensed, and then signalled up to the varying apoptosis pathways and mechanisms. The two serine/threonine protein kinases ATR and ATM are key factors involved in the DNA

damage response, but there are only a few reports describing how they function in apoptosis signalling ¹⁹. ATM has been linked to cytokine and caspase signalling upon strong genotoxic damage as well as to PIDD phosphorylation required for RAIDD binding and caspase-2 activation ^{16, 20}. However, very little is known how these responses vary based on treatment type and molecular make-up of cancer cells.

Given the growing complexity of how different cancer treatments trigger various cell death mechanisms, it is important to unravel the cellular and molecular contexts that determine the utilisation of the various pathways in cancer cells, and to exploit this new knowledge for diagnostic and therapeutic purposes.

Results

5FU-induced apoptosis is mediated by a caspase-9- and RIPoptosome-independent process that is initiated by caspase-8

In order to reduce the complexity caused by overlapping cell death modi we applied a prescreen to identify compounds that act solely through apoptosis mechanisms that have not been previously described with the aim of identifying novel pathways (Figure 1a). Through this experimental strategy, we found that 5FU induces apoptosis via a potentially novel mechanism (Supplementary Figures 1a-e). AnnexinV/PI staining, DNA hypodiploidy assays, caspase Western blots and measurements of mitochondrial membrane potential (MMP) of cells treated with 5FU alone or in combination with zVAD confirmed that 5FU induces apoptosis and other apoptotic processes in a caspase-dependent manner (Figure 1b and Supplementary Figures 2a-d). To test the causal involvement of caspase-8 as initiator caspase we knocked-out caspase-8 by CRISPR/Cas9 gene editing and found that these cells were resistant to 5FU-induced apoptosis (Figure 1c). Silencing of caspase-8 by RNAi confirmed these findings, whereas targeting of caspase-2 and caspase-9 had no significant impact on cell death levels (Supplementary Figures 2e-k). In contrast, Etoposide-induced cell death was not affected by silencing or knock-out of caspase-8 (Supplementary Figures 2e and 2l). Silencing of cFLIP did not significantly impact on 5FU-induced apoptosis in HCT116 cells (Supplementary Figure 2m). Additionally, while 5FU showed caspase-8 activity in a luciferase-based assay, Etoposide did not (Figure 1d and Supplementary Figure 2n). To validate and verify caspase-8 as the proximal caspase in 5FU-induced apoptosis, we carried out a molecular trapping assay using a biotinylated caspase inhibitor (bVAD). For 5FU treated HCT116 cells this assay revealed caspase-8 as the initiator caspase, whereas caspase-9 and caspase-2 could not be detected (Figure 1e). While not all drugs acted via this pathway, e.g. Etoposide, others also required the presence of caspase-8 such as Raltitrexed or the topoisomerase I inhibitor Irinotecan

(Supplementary Figure 2o). To test the impact of caspase-8 on clonogenicity and relevance in 5FU responses *in vivo*, we carried out colony forming assays (CFAs) and established xenografts. The CFAs revealed that silencing of caspase-8 allowed substantial survival and outgrowth, in contrast to controls (Supplementary Figure 2p). Similar results were obtained in the xenograft study (Figure 1f and Supplementary Figure 2q).

Caspase-8 activation is p53- and death receptor-independent

Next, we analysed whether 5FU-induced caspase-8 activation was p53 dependent²¹. We compared p53-proficient HCT116 and HCTp53^{-/-} cells for caspase-8 activity following 5FU treatment. Despite lower apoptosis levels in the p53-null cells (Figure 2a), caspase-8 activation was unchanged in these cells as compared to their isogenic parental cells (Figure 2b). The importance of caspase-8 even in the p53-null context was underscored by the fact that apoptosis, albeit at overall low levels, was significantly reduced by silencing of caspase-8 (Figure 2c). As mitochondrial depolarisation in response to 5FU was lower in HCTp53^{-/-} than in HCT116 cells (Figure 2d) it appears that the signal from activated caspase-8 onto mitochondria was attenuated in the p53-negative cells resulting in diminished caspase-3 activation. Activated caspase-8 signals to mitochondria via the BH3-only protein Bid. When we silenced Bid in HCT116 cells (HCT.shBid), we found significantly decreased apoptosis and mitochondrial depolarisation after treatment with 5FU, but no reduction in caspase-8 activity (Figures 2e and 2f and Supplementary Figure 3a). Thus, Bid is an essential signalling intermediate in 5FU-induced apoptosis, necessary for mitochondrial activation. As we demonstrated that caspase-9 is not required, we hypothesised that not cytochrome c, but other factors, Smac/DIABLO in particular, are important to overcome XIAP-enforced inhibition of executioner caspase activation. We therefore, silenced XIAP in HCT.shBid cells, mimicking the release of Smac/DIABLO, and treated with 5FU. Such cells showed restored

apoptosis and caspase-3 activation to almost parental HCT116 levels (Figure 2g and Supplementary Figure 3b). Similarly, when we knocked down XIAP in p53-silenced cells we observed the same increase in apoptosis (Figure 2h). Thus, p53 is involved in the execution of 5FU-induced apoptosis via engagement of mitochondria, but not needed for the initiation of cell death at the level of caspase-8 activation.

Caspase-10 is upregulated in response to 5FU in a p53-independent manner and forms a complex with FADD and caspase-8

In order to elucidate the underlying mechanism of caspase-8 activation in response to 5FU, we carried out an RNA-Seq analysis. From 568 genes that were significantly upregulated (Supplementary Table 1), five were potential caspase-8 binding partners and also upregulated as proteins (Figures 3a and 3b and Supplementary Table 2). Of these, CD95, TRAIL-R1 (TNFRSF10A) and TRAIL-R2 (TNFRSF10B) are p53-target genes and were therefore not good candidates as drivers for 5FU-induced, p53-independent caspase-8 activation. Furthermore, blocking these receptors with neutralising antibodies caused no change in apoptosis levels (Supplementary Figure 4a). As Caspase-10 and cIAP2 upregulations were p53-independent (Figure 3c), we tested their capacity to induce apoptosis in HCT116 cells as compared to HCT.shC8 cells. Forced expression of caspase-10 but not cIAP2 gave rise to caspase-8-driven apoptosis implicating caspase-10 in the formation of the caspase-8 activation complex (Figure 3d and Supplementary Figure 4b). Indeed, when we immunoprecipitated caspase-8 from 5FU-treated HCT116 cells we could detect coprecipitation of processed caspase-10 and the adaptor protein FADD, but not cIAP2 or the death receptors (Figure 3e and Supplementary Figure 4c). These results were confirmed in caspase-10 overexpressing cells, i.e. after immunoprecipitation with caspase-8 antibodies, we were able to detect caspase-10 and FADD (Figure 3f). Furthermore, when we pulled-down

overexpressed tagged versions of FADD in 5FU-treated 293 cells we were able to co-precipitate caspase-8 and caspase-10, and could also demonstrate FADD multimerisation in these cells (Supplementary Figure 4d). Thus, an induced complex containing FADD, caspase-10, and caspase-8 appeared to be responsible for the activation of caspase-8 and apoptosis induction. The formation of such a complex was corroborated by a sucrose gradient analysis that showed a shift of caspase-8, FADD and caspase-10 to higher molecular weight fractions (~2 MDa) after 5FU treatment (Supplementary Figure 4e). This shift of FADD and caspase-10 was absent in HCT.shC8 cells, but not in HCT.shBid cells, demonstrating the specificity of the analysis (Supplementary Figure 4f). To further elucidate the role of FADD and caspase-10, we generated respective knock-down cell lines (Supplementary Figure 4g). Silencing of FADD in HCT116 and HT-29 cells resulted in inhibition of both 5FU-induced apoptosis and caspase-8 activation (Figures 3g and 3h), as well as a lack of a shift of caspase-8 and caspase-10 in sucrose gradient analyses (Supplementary Figure 4h). On the other side knocking down of caspase-10 surprisingly led to significantly increased levels of cell death, which could still be blocked by the caspase inhibitor zVAD (Figure 3i and Supplementary Figure 4i). Thus, apoptosis in HCT.shC10 cells is a caspase-dependent process similar to HCT116 cells, but the markedly higher levels pointed to a potentially different and distinct mechanism in these cells.

Lack of Caspase-10 leads to TNF- α production in response to 5FU and FADD-independent apoptosis

Studying HCT.shC10 cells in more detail revealed, that similar to HCT116 cells, 5FU led to caspase-8 activation and caspase-8-dependent cell death, but silencing of FADD in HCT.shC10 cells did not result in apoptosis resistance (Figure 4a). The FADD-independency was confirmed by a lack of FADD multimerisation in HCT.shC10 cells in response to 5FU and a lack of a shift of

FADD in sucrose gradient analyses (Supplementary Figure 5a). These results indicate that caspase-10 deficiency indeed leads to a switch to a different apoptosis mechanism. Next, we examined whether death receptors/death ligands were behind 5FU-induced caspase-8 activation and apoptosis in caspase-10 knock-down cells. While both FasL and TRAIL-blocking antibodies did not affect cell death levels, antibodies directed against TNF- α and its receptor TNFR1 significantly decreased apoptosis (Figure 4b and Supplementary Figure 5b). As this was not the case in HCT116 cells (Supplementary Figure 5b), we concluded that in HCT.shC10 cells 5FU triggered the production of TNF- α , which in turn gave rise to apoptosis. An ELISA of supernatants from HCT.shC10 cells confirmed the TNF- α generation (Figure 4c). In addition, we discovered that I κ B- α was phosphorylated and degraded in HCT.shC10, but not in control cells indicating that 5FU-induced NF- κ B activation gave rise to TNF- α upregulation (Figure 4d). Blocking NF- κ B activation by overexpression of I κ B-SR in HCT.shC10 cells stopped the 5FU-induced TNF- α production and inhibited apoptosis (Figure 4e and Supplementary Figure 5c). Cell death and TNF- α generation could also be blocked by silencing of caspase-8 in HCT.shC10 cells demonstrating that caspase-8 was not only required for the TNF- α -induced apoptosis, but was also crucial for the production of the cytokine in the first place (Figure 4f). Having excluded FADD as a functional partner in caspase-8 activation in HCT.shC10 cells, we turned to another known caspase-8 binding partner, cFLIP. We discovered that cFLIP_L was degraded in HCT116 cells following 5FU treatment, but in HCT.shC10 cells the cFLIP_L levels hardly changed, and instead a cleaved form of cFLIP_L, cFLIP_{p43}, appeared (Figure 4g). A more detailed analysis revealed that cleavage of cFLIP_L to cFLIP_{p43} is required for TNF- α production, as both cFLIP_L and cFLIP_{p43}, but not the cleavage-mutant cFLIP_{D376N}, were capable of turning on TNF- α generation after 5-FU treatment (Figure 4h). In contrast, silencing of cFLIP in HCT.shC10 cells gave rise to significantly reduced

TNF- α production in response to 5FU (Figure 4i). When we overexpressed cFLIP_L and cFLIP_{p43} in caspase-8 silenced cells we found that neither of the two was able to induce TNF- α production demonstrating that caspase-8 activity was not only needed to cleave cFLIP_L, but also required as a platform to facilitate NF- κ B activation (Figure 4j). As for the prominent role of cFLIP in the complex triggering TNF- α production, we termed this complex FLIPosome consisting of caspase-8 and cFLIP_L (Figure 4k), whereas the caspase-8 activation complex in HCT116 cells was named FADDosome in recognition of the central role of FADD therein. In order to examine the utility of switching tumour cells to drug-induced TNF- α production as a sensitisation approach, we used HCT.shC10 cells in an *in vivo* study. We found that HCT.shC10 xenografts responded significantly better to 5FU than control xenografts (Figure 4l and Supplementary Figures 5d and 5e).

TRAF2 is recruited to the FADDosome by caspase-10 and RIP1 and is responsible for cFLIP_L ubiquitination and degradation

TNF- α production and its involvement in apoptosis has been described in the context of other apoptosis inducing mechanisms e.g. the action of IAP inhibitors or TNF- α feedforward signalling. We were therefore interested whether these cell death mechanisms and complexes are comparable to the FLIPosome. Another key feature of these pathways and also the RIPosome is the degradation of IAPs, and indeed cIAP1 was degraded in response to 5FU in caspase-10 silenced cells (Figure 5a). RIP1 has been described as a core and essential component of the mentioned apoptosis mechanisms. However, when we measured apoptosis in HCT.shC10.shRIP1 double knock-down cells, we did not observe diminished cell death, ruling out a role for RIP1 and the RIPosome (Figure 5b). Interestingly, we discovered that in single RIP1 knock-down cells (HCT.shRIP1) apoptosis was higher than in HCT.shctrl cells closely resembling HCT.shC10 cells (Figure 5b and Supplementary Figure 6a). Again, both cIAP1 and I κ B- α were degraded in

HCT.shRIP1 cells and TNF- α was produced in response to 5FU, which could be inhibited by I κ B-SR expression (Figure 5c and Supplementary Figure 6b). Hence, while RIP1 is not a critical factor for apoptosis, it is an essential factor for FADDosome formation, and RIP1 deficiency instead leads to the FLIPosome.

As we showed that proteolytic degradation of cFLIP_L is a hallmark of the FADDosome, we set out next to identify the E3 ubiquitin ligase activity that binds within the FADDosome and initiates the proteolytic pathway. We analysed three candidate proteins, TRAF2, cIAP1 and cIAP2, which possess ubiquitin ligase activity and are known to be principally able to interact with FADDosome constituents. Co-IPs revealed that in addition to FADD and caspase-10, RIP1 and TRAF2 were bound to caspase-8 after 5-FU treatment (Figure 5d). This finding was strengthened by the fact that caspase-8 activity could be precipitated with RIP1 (Supplementary Figure 6c). When we knocked down TRAF2 in HCT116 cells (HCT.shTRAF2) we detected, similarly to HCT.shC10 and HCT.shRIP1 cells, higher apoptosis levels in response to 5FU and TNF- α production that could be blocked by I κ B-SR (Figure 5e and Supplementary Figures 6d and 6e). Thus, the FADDosome was expanded by two additional factors, RIP1 and TRAF2. Furthermore, when we overexpressed TRAF2 we saw ubiquitination of cFLIP_L, which was absent in cells overexpressing a TRAF2- Δ RING variant lacking ubiquitin ligase activity as well as in cells overexpressing cIAP1 or cIAP2 (Figure 5f and Supplementary Figure 6f). Similarly, we found cFLIP_L degradation in 5FU-stimulated control HCT116 cells expressing either EGFP or TRAF2, but not in the TRAF2- Δ RING sample, which, acting in a dominant-negative manner, blocks cFLIP_L degradation (Figure 5g). These results demonstrate that TRAF2 is likely to be the ubiquitin ligase that is recruited to the FADDosome where it mediates cFLIP ubiquitination and degradation. In addition, RIP1 and caspase-10 are required for the TRAF2 recruitment and subsequent molecular processes and absence of any of the three factors leads to apoptosis through FLIPosome action instead.

ATR is essential for caspase-10 upregulation and FADDosome formation

Finally, we wondered how the cellular damage inflicted by cytotoxic drugs is translated into apoptosis signals inside the treated cells. Most chemotherapeutic drugs cause DNA damage, with 5FU additionally being able to give rise to perturbation in RNA metabolism. DNA damage activates the ATM and ATR kinases via autocatalytic phosphorylation. Once activated, they phosphorylate a plethora of proteins that control and repair DNA damage, but only very few direct molecular links to apoptosis induction have been established. When we checked for ATM and ATR activation in response to 5FU, we found only ATR to be phosphorylated, whereas with Etoposide we obtained reverse results, i.e. only ATM was phosphorylated (Figure 6a and Supplementary Figure 7a). Thus, we silenced ATR in HCT116 cells (HCT.shATR) (Supplementary Figure 7b) and also used the ATR inhibitor AZD6738 in combination with 5FU. When we measured apoptosis in these cells we discovered that both ATR silencing and AZD6738 caused significantly increased apoptosis (Figure 6b). An ELISA of the supernatants of 5FU-stimulated HCT.shATR cells, as well as ATR inhibitor co-treated cells, detected TNF- α production, resembling the situation in HCT.shC10 cells. It appeared that cells lacking ATR activity engaged the FLIPosome to initiate apoptosis (Figure 6c). A subsequent Western blot analysis revealed that caspase-10 was no longer upregulated in cells with knocked-down or blocked ATR (Figure 6d). Furthermore, blocking ATR led to inhibition of Chk1 phosphorylation and p53 activation in response to 5FU (Figure 6d). Furthermore, we found the FLIPosome to act in a p53-independent manner (Supplementary Figures 7c-e) and that a specific Thymidylate Synthase (TS) inhibitor (Raltitrexed) could only give rise to FADDosome-mediated apoptosis, but was unable to trigger TNF- α production (Supplementary Figures 7f-h). These findings reveal a novel ATR-caspase-10 axis and also provide new insights into the mechanism of ATR inhibitors, such as AZD6738, in cancer treatment.

Discussion

Despite the evident importance of treatment-induced cell death induction in cancer cells, knowledge of the molecular steps that initiate and progress the apoptotic signalling cascade remain sketchy. However, a detailed understanding of the molecular event(s) leading to apoptosis is crucial for the development of improved diagnostic and predictive tools as well as novel therapeutic approaches.

We found that drugs that are known to give rise to replication stress and consequent single-strand DNA breaks lead to caspase-8 initiated apoptosis. These findings are in contrast to the consensus view that caspase-9 initiates the apoptosis cascade in response to cytotoxic drugs and other intracellular stressors^{22, 23}. The observed caspase-8 activation was independent of death-receptor triggering, in contrast to what was shown in the past for other cytotoxic drugs in different cancer cells^{24, 25}. As RIP1 was also not essential for apoptosis, ruling out the RIPosome or TNF- α feedforward signalling, we concluded that a novel caspase-8 mechanism must be responsible, for which our results suggest the following model (Figure 7). In response to treatment, ATR detects the drug-produced DNA lesions and elicits upstream signals that are responsible for the p53-independent caspase-10 upregulation. This provides the germ for the subsequent formation of the FADDosome, which aside from caspase-10, contains FADD, caspase-8, RIP1 and TRAF2 (Figure 7a). Within the FADDosome, cFLIP_L is ubiquitinated by TRAF2 leading to its degradation. Interestingly, in the TRAIL DISC it is not cFLIP_L but its sibling molecule caspase-8 that is ubiquitinated by TRAF2 pointing to context-specific activities and effects²⁶. Caspase-8, FADD, caspase-10, TRAF2 and also RIP1 as well as ATR are all required for FADDosome formation, with the latter four factors being dispensable for apoptosis. In the absence of these factors, cells switch to an alternative mechanism that involves a complex we termed FLIPosome and caspase-8-mediated cleavage of cFLIP_L to cFLIP_{p43} comparable to findings in the CD95 DISC^{27, 28} (Figure

7b). This results in NF- κ B activation that drives expression of TNF- α , causing apoptosis in an autocrine and paracrine fashion. FLIPosome-induced apoptosis is, in contrast to the FADDosome, FADD- and p53-independent, providing distinct therapeutic advantages in solid tumours harbouring dysfunctional p53. The fact that both FADD as well as RIP1 are dispensable for the FLIPosome distinguishes it also from the RIPoptosome as well as the TNF- α feedforward signalling pathway^{14, 16}. Our results demonstrate that the FLIPosome is the more efficacious apoptosis mechanism as also evident by the increased 5FU responsiveness in xenografts derived from caspase-10 silenced cells. Thus, flicking the switch from cell autonomous apoptosis to non-autonomous cell death via the TNF- α -pathway provides a potential new avenue to overcome resistance in tumour cells and/or increase treatment efficacy. The latter type of apoptosis, also known as “communal death” normally plays a role in tightly regulated developmental processes, which require a coordinated cell death response²⁹. It is a conserved mechanism found in flies and mammals that has also been implicated in the synchronous apoptosis wave observed in certain pathologies such as cardiac infarction and alcohol-/drug-induced liver failure^{30, 31, 32}. Our results indicate that tumour cells have either maintained or are able to reactivate this archaic pathway that it is controlled by caspase-10. Our results regarding a regulatory but not directly apoptotic activity of caspase-10 are not dissimilar to findings about its role in the CD95 and TRAIL DISCs³³ indicating a general role in orchestrating caspase-8 activation and cellular fate. Importantly, the *caspase-10* gene has been shown to be lost in mice^{34, 35}. As they are commonly used in the study of cancer treatments including apoptosis pathways, caution should be exercised when transferring results obtained in murine rodents to the human setting.

Our results also indicate a novel mode of action of ATR inhibitors when used in combination with other treatments as has been widely proposed. Owing to blocked DNA repair, such cells appear to respond with the more fulminate FLIPosome/TNF- α -mediated cell death type including systemic

anti-tumour functions of the immune system. These approaches also have the added advantage to be effective in p53-null cells. Having delineated the described apoptosis mechanisms and pathways offers several targets to interfere with and to engage at least one of the two different routes to apoptosis in order to bypass resistance points in cancer cells.

Methods

Reagents. All chemicals, unless otherwise stated, were purchased from Sigma. Pancaspase inhibitor zVAD.fmk (zVAD) was from Santa Cruz Biotechnology and biotinylated-VAD.fmk (bVAD) was bought from Calbiochem. Recombinant CD95L was purchased from Enzo Life Sciences. Recombinant TRAIL was purchased from R&D Systems. Recombinant TNF- α was purchased from Peprotech. The ATR inhibitor AZD6738, Raltitrexed and Irinotecan were bought from Stratech.

Antibodies. Sheep anti-CuZnSOD (The Binding Site), goat and mouse anti-actin (Santa Cruz Biotechnology), rabbit anti-TRAIL-R2 (Cell Signaling Technology), mouse anti-caspase-3 (Imgenex), mouse anti-caspase-8 (Cell Signaling Technology, Santa Cruz Biotechnology and BD Biosciences), mouse anti-XIAP (BD Biosciences), mouse-anti-cFLIP (AdipoGen), goat anti-cIAP1 (R&D Systems), rat anti-cIAP2 (Enzo Life Sciences), mouse anti-caspase-9 (Novus Biologicals), mouse anti-caspase-2 (BD Biosciences), mouse anti-CD178 (BD Biosciences), mouse anti-TNFR1 (Santa Cruz Biotechnology), rabbit anti-TRAIL (Peprotech), rabbit anti-TRAIL-R1 (Santa Cruz Biotechnology), mouse anti-TNFR1 (Hycult Biotech), mouse anti-FADD (Millipore), rabbit anti-Bid (R&D Systems), mouse anti-RIP1 (BD Biosciences), mouse anti-p53 (BD Biosciences), mouse anti-caspase-10 (MBL), rabbit anti-CD95 (Santa Cruz Biotechnology), mouse anti-TRAF2 (Santa Cruz Biotechnology), rabbit anti-TRADD (Cell Signaling Technology), rabbit anti-CRADD/RAIDD (Cell Signaling Technology), rabbit anti-NEMO (Santa Cruz Biotechnology), mouse anti-Myc (Santa Cruz Biotechnology), mouse anti-V5 (Thermo Fisher Scientific), rabbit anti-I κ B- α (Cell Signaling Technology), rabbit anti-Phospho-I κ B- α (Cell Signaling Technology), rabbit anti-Phospho-ATR (GeneTex), rabbit anti-ATR (Bethyl Laboratories), rabbit anti-Phospho-ATM (Cell Signaling Technology), mouse anti-ATM (Sigma), rabbit anti-Phospho-Chk1 (Cell Signaling Technology), mouse anti-Chk1 (Cell Signaling Technology), mouse anti-TNF- α

(Biolegend), IgG1 Isotype antibody (BD Biosciences), IgG2a Isotype antibody (Biolegend), IgG2b Isotype antibody (Biolegend), mouse anti-Smac/DIABLO antibody (Abcam), FITC-conjugated F(ab')₂ anti-mouse IgG2a antibody (Southern Biotechnology), FITC-conjugated F(ab')₂ anti-mouse IgG2b antibody (Southern Biotechnology), mouse anti-cytochrome c (BD Biosciences). Peroxidase-conjugated secondary antibodies were anti-mouse, anti-rabbit, anti-goat, anti-rat and anti-sheep (Santa Cruz Biotechnology). For co-immunoprecipitations TrueBlot peroxidase-conjugated secondary antibodies were used (Rockland).

Cell lines. Human colorectal tumour HCT116 cells (ATCC), their isogenic daughter cell line HCTp53^{-/-} (gift from Bert Vogelstein) and HT-29 (ATCC) cells were grown in McCoy's (Lonza) supplemented with 10% FBS (Life Technologies), 100 U/ml penicillin and 100 µg/ml streptomycin. Human ovarian cancer cell line A2780 (Sigma) was grown in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Human cervix carcinoma HeLa cells (ATCC) and human breast carcinoma MDA-MB-231 cells (ATCC) were grown in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin.

Overexpression constructs. Flag-cIAP2/pRK5 was a gift from Xiaolu Yang (Addgene plasmid # 27973)³⁶, pcdna3.1 hciap1 was a gift from Jon Ashwell (Addgene plasmid # 8311)³⁷. HA-Ubiquitin was a gift from Edward Yeh (Addgene plasmid # 18712)³⁸. Caspase-10 was purchased from Invivogen. TRAF2, pCMV6.FADD.MYC and cFLIP were bought from Origene. Generation of cFLIP constructs: cFLIP_L was cloned into pcDNA3.1/V5-His TOPO-TA (Life Technologies). cFLIP_{p43} was generated by PCR and cloned into pcDNA3.1/V5-His TOPO-TA (Life Technologies). The 3'-PCR primer contains a stop codon, so that the V5-His tag is not expressed. FLIP_{D376N} was generated by site-directed mutagenesis of the cFLIP_L construct using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). Generation of TRAF2

constructs: TRAF2 Δ Ring was generated by PCR and along full-length TRAF2 cloned into pcDNA3.1. Generation of FADD constructs: To obtain two differently tagged FADD constructs, FADD was also cloned into pcDNA3.1/V5-His TOPO-TA (Life Technologies) by PCR. The resulting construct was termed pcDNA.FADD.V5. Generated constructs were validated by sequencing.

Knock-down constructs and stable cell line generation. The following small hairpin (sh) RNA motifs were used to target XIAP (shXIAP)³⁹, caspase-8 (shC8)⁴⁰, caspase-2 (shC2) (5'-GACAGCTGTTGTTGAGCGAA-3'), caspase-10 (shC10) (5'-GCATTGACTCAGAGAACTTAA-3'), Bid (shBid)⁴⁰, FADD (shFADD) (5'-GTGCAGCATTAAACGTCAT-3'), RIP1 (shRIP) (5'-GCTGCTAAGTACCAAGCTATC-3'), cFLIP (shFLIP)⁴¹, TRAF2 (shTRAF2)⁴², p53 (shp53)⁴³, caspase-9 (shC9)⁴⁴, EGFP (shEGFP)⁴⁴, ATR (shATR)⁴⁵, scrambled (shsc) (5'-GCGTAAGTCGCACGTCACACA-3'), Lamin A/C (shLamin) (Life Technologies). Sense and antisense oligos containing the short-hairpin sequence were hybridised to generate double-stranded DNA fragments. These fragments were then cloned into a modified pU6.ENTR plasmid (Life Technologies). The resulting pU6.ENTR plasmids were used to generate the pAd.sh plasmids using the LR Clonase II system (Life Technologies). Furthermore, the pU6.ENTR plasmids were used to generate the pBlockiT.sh plasmids (Life Technologies) to generate stable knock-downs. For this, the respective pBlockiT.sh plasmids were FuGene HD transfected into cells. Three days later, the transfected cells were split into Blasticidin containing selection medium. Arising clones were picked, transferred to 24-well plates and tested for gene silencing. Moreover, shLamin clones, which were generated by transfection with the pBlockiT6-GW/U6-lamin.shRNA plasmid, served as RNAi controls (Figure S7b and S7b). To generate the shC10/shFADD, shC10/shRIP1, shC10/shC8 and shC10/shp53 double knock-down clones, we generated shFADD, shRIP1, shC8 and shp53 RNAi plasmids in psiRNA-h7SKzeo

(InvivoGen). For this, we ligated the double-stranded DNA fragment, containing the respective motifs into the BbsI- (Bpi1; Fisher Scientific) opened psiRNA-h7SKzeo vector. The resulting plasmids were FuGene HD transfected into HCT.shC10 cells. Following the same procedure as described above, the cells were selected in Zeocin (InvivoGen) containing medium. A clone generated with empty plasmids served as HCT.shctrl cells.

Generation of knock-out cell lines via CRISPR/Cas9. Sequences of gRNAs were selected according to the Zhang lab. The respective gRNAs were inserted into the pX459 V2.0 plasmid as previously described ⁴⁶. HCT116 cells were transfected with the respective pX459 V2.0 gRNA plasmid. 24 h post transfection, positive cells were selected using puromycin prior to clonal expansion in normal growth medium. After 3-4 weeks, clones were screened for knock-out by immunoblot.

Generation of adenoviral vectors and transduction. Adenoviral vectors expressing cFLIP_L (Ad.cFLIP_L) and dominant negative caspase-9 (Ad.DN-C9) were purchased from Vector Biolabs. IκB-SR (Ad.IκBSR), DsRed (Ad.DsRed) and enhanced green fluorescent protein (EGFP; Ad.EGFP) were described previously ^{39,47,48}. Adenoviral vectors encoding small hairpin constructs were generated using the ViraPower adenoviral expression system (Life Technologies). Adenoviral vectors encoding small hairpin constructs were targeted against EGFP, cFLIP, caspase-8, caspase-2, caspase-9, XIAP, and p53 genes, respectively. The vectors were named Ad.shEGFP, Ad.shcFLIP, Ad.shC8, Ad.shC2, Ad.shC9, Ad.shXIAP and Ad.shp53. A vector expressing a scrambled shRNA (Ad.shsc) served as additional control. For adenoviral transduction, the normal growth medium was changed to medium with 2% FBS. The cells were transduced with virus at 200 pfu/cell for 6 hours and then washed off.

Apoptosis measurements. To determine drug induced cell death, cells were stimulated with 200 μM 5FU (48 h), 50 μM Raltitrexed (72 h), 10 μM Irinotecan (48 h) or 100 μM etoposide (48 h),

respectively. The pancaspase inhibitor zVAD was used at 20 μ M and incubated for 4 h as pre-treatment before 5FU was added. *DNA-hypodiploidy staining*: Cells including their medium supernatant and PBS wash were harvested and centrifuged at 1,300 rpm for 7 min at 4° C. After washing with PBS, Nicoletti buffer (Sodium citrate 0.1 % (w/v) containing 0.1 % Triton X-100 (w/v) and propidium iodide 50 μ g/ml)⁴⁹ was added to the cell pellets, tubes were vortexed for 10 s at medium speed and left for 5 h in the dark (4° C). The fluorescence intensity was then measured in a flow cytometer and analysed with the Venturi One software package (Applied Cytometry). Normally, absolute apoptosis levels are depicted, but when specific apoptosis is shown, it was determined by subtraction of the basal apoptosis values from the cell death levels of treated cells. *AnnexinV/PI staining*. The AnnexinV/PI staining was carried out as follows: Cells were treated with 5FU and harvested 48 h later. Cells were then trypsinised and spun down at 1,300 rpm for 7 min at 4°C. Subsequently, cells were washed with binding buffer (10 mM HEPES NaOH [pH 7.4], 150 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1.8 mM CaCl₂) and recentrifuged. The cell pellets were resuspended in binding buffer containing AnnexinV (Roche) at a final concentration of 2.5 μ g/ml and incubated for 15 min at 4° C in the dark. Shortly before the measurement, PI solution was added at a final concentration of 2 μ g/ml in binding buffer prior to analysis.

Necrosis measurement. *Loss of plasma membrane integrity*: Cells were harvested and washed in PBS, centrifuged at 1,300 rpm for 5 minutes, and then resuspended in 100 μ l PBS. Shortly before FACS measurement, PI (to 2 μ g/ml) was added.

Clonogenic assay. HCT.shctrl and HCTshC8 cells were treated with 200 μ M 5FU for 15 h before 10,000 cells were seeded in normal growth medium. After three weeks resulting colonies were fixed in 2% paraformaldehyde (PFA) and visualised with a 0.04% crystal violet solution. Colonies were then counted.

Neutralising antibody and death ligand treatments. Cells were pretreated with the following antibodies: anti-CD178 (NOK1) (25 µg/ml), anti-TRAIL (0.5 µg/ml) and anti-TNF- α (10 µg/ml) for 5 h, followed by 5FU stimulation for 48 h. The efficacy of the antibodies was tested by stimulating with their respective ligands. In this context, cells were pretreated as described above, before addition of the respective death-ligands. CD95L was used at a concentration of 250 ng/ml and TRAIL at a concentration of 5 ng/ml for 48 h. Cells were pre-treated with anti-TNFR1 antibody (Hycult Biotech) (100 µg/ml) for 24 h, followed by 5FU and anti-TNFR1 cotreatment.

Measurement of the mitochondrial membrane potential. Perturbations in mitochondrial transmembrane potential were monitored by flow cytometry. Cells were treated with 200 µM 5FU for 24 h, or left untreated as control. Following drug treatment, cells were harvested and washed with prewarmed PBS. The cells were then labelled with 2 nM DIOC6(3) (Thermo Fisher Scientific) at 37° C for 20 min and subsequently analysed by FACS.

Cytochrome c measurements. HCT116 cells were either pretreated with 20 µM zVAD for 4 h or left untreated before 5FU was added for 48 h. FACS analysis of cytochrome c release was performed according to a previously described protocol⁵⁰. Cytochrome c release is detected as a drop in the fluorescent signal.

Smac/DIABLO release. HCT116 cells were either pretreated with 20 µM zVAD for 4 h or left untreated before 5FU was added for 48 h, harvested and prefixed with 0.01% PFA for 20 min at 4° C. Prefixation was followed by an additional fixation step with 0.12% PFA for 20 min before the cells were permeabilised with 0.1% Saponin for 5 min at 4° C. Next, mouse IgG1 was added (50 µg/ml) for 20 min at 4° C, followed by 1 µg/ml anti-Smac/DIABLO antibody for an additional 20 min at 4° C. IgG2a isotype antibody was used as control. For Smac/DIABLO staining, the cells were incubated with FITC-conjugated goat F(ab')₂ anti-mouse IgG2a antibody (1:20) for 20 min

at 4° C in the dark. Samples were then analysed by FACS. Smac/DIABLO release is detected as an increase in the fluorescent signal.

Western blot. Proteins were separated by SDS-PAGE and transferred onto PVDF membranes (GE Healthcare Biosciences). Primary and secondary antibodies were diluted in TBS, 0.1% Tween and 3% BSA. Bands were visualised with ECL Western blotting substrate (Thermo Fisher Scientific). CuZnSOD served as loading control.

TNF- α Enzyme-Linked Immunosorbent Assay (ELISA). To examine TNF- α levels, we plated 1×10^7 cells in a 15 cm dish. We transduced or transfected the cells 24 h before 5FU stimulation. Cells were stimulated with 100 μ M 5FU for 24 h before medium was exchanged to zVAD (20 μ M) containing serum-free medium (UltraCULTURE, Lonza). After 72 h cell culture supernatants were cleared and concentrated 5-fold. For concentrating of supernatants we used Amicon Ultra-centrifugal Filters (3 kDa). A commercial TNF- α ELISA Kit (R&D Systems) was used following the manufacturer's instructions.

Cytokine Array. For these studies, we took blood from two mice of each treatment group at the end of each experiment and separated serum from whole blood. The respective sera were diluted 1:5 and applied to mouse cytokine antibody arrays III (RayBio) according to manufacturer's instructions. We normalised each cytokine signal to its internal control and compared each treatment group (PBS treated HCT.shctrl animals with PBS treated HCT.shC10 animals [PBS] and 5FU treated HCT.shctrl animals with 5FU treated HCT.shC10 animals [5FU]) with each other and expressed changes in caspase-10 silenced xenografts in different colours. We used a two colour scale from green (≤ 1.5 fold change) to red (≥ 5 fold change).

Sucrose density gradient fractionation. The sucrose gradient protocol was adapted from Feig et al. ⁵¹. Briefly, cells were treated with 5FU for 24 h before they were harvested, washed once with ice-cold PBS and resuspended in 1% Triton X-100 buffer (30 mM Tris-HCl [pH 7.5]; 150 mM

NaCl; 2.5 mM EDTA; 10% (v/v) glycerol; 1% (v/v) Triton X-100; Protease inhibitors). Cell lysis was carried out for 10 min on ice and lysates were cleared of debris by centrifugation at 14,000 rpm for 10 min at 4° C. The protein lysate (1.5 mg) was overlaid on top of the sucrose gradient (10 - 50% (w/w) sucrose), which was then subjected to ultracentrifugation at 37,500 rpm for 16 h. 14 equal fractions were then collected and subjected to SDS-PAGE and Western blotting for proteins of interest.

Immunoprecipitation experiments. Cells were plated overnight and stimulated with 5FU for 24 h unless otherwise indicated. Cells were collected, washed in ice-cold PBS, and lysed in the appropriate immunoprecipitation buffer containing protease inhibitor cocktail tablets (Roche). For the caspase-8 immunoprecipitation, cells were lysed in NP-40 buffer (50 mM Tris [pH 7.4]; 10% glycerol; 0.5% NP40; 150 mM NaCl; 1mM MgCl₂; 1 mM CaCl₂; 1 mM KCl; Protease inhibitors). The caspase-8 antibody (Santa Cruz Biotechnology) was used at a concentration of 1 µg/mg protein and cross-linked to Protein A/G agarose (Pierce Crosslink IP Kit, Thermo Fisher Scientific). For the Myc-tag immunoprecipitation, cells were plated overnight and followed by co-transfection with pCMV6.FADD.MYC and pcDNA.FADD.V5 expression plasmids at equal amounts of DNA. 5 h post-transfection, the medium was changed and after an additional 5 h, cells were stimulated with 5FU for 15 h. Cells were treated with Etoposide (150 µM) 12 h after the change of medium for another 15 h. Untreated transfected cells served as controls. Cells were lysed in RIPA buffer (50mM Tris-HCl [pH 7.4]; 150mM NaCl; 2mM EDTA; 1% NP-40; 0.1% SDS; Protease inhibitors). The Myc antibody was used at a concentration of 1 µg/mg protein and captured with magnetic beads pre-coated with anti-mouse antibodies.

For the RIP1, caspase-8 and actin immunoprecipitations used in the caspase-8 activity assays, cells were lysed in NP-40 buffer. The antibodies were used at a concentration of 1 µg/mg protein and

captured with Protein A/G agarose (caspase-8 and actin IP) or magnetic beads pre-coated with anti-mouse antibodies (RIP1 and actin IP).

Caspase-8 activity assay. Caspase-8 activity was measured after caspase-8, actin and RIP1 immunoprecipitations, respectively. The caspase-8 and RIP1 immunoprecipitations were performed as described above with one additional wash with cold aqua bidest included after the magnetic beads were washed 5 times with lysis buffer. Finally, the beads were resuspended in 100 μ l aqua bidest followed by addition of 100 μ l of Caspase-8 Glo buffer (Promega). Luminescent readings were carried out and samples were analysed after 1 h.

***In-situ* trapping and streptavidin-precipitation of biotinylated initiator caspases.** This method was performed according to a previously described protocol ⁵². Cells were pretreated with 50 μ M bVAD for 2 h in their normal growth medium and under normal culture conditions before 5FU was added. After 5FU stimulation (18 h), cells were harvested and protein lysates prepared as described previously ⁷. These protein lysates were subsequently mixed with streptavidin-conjugated magnetic beads (Thermo Fisher Scientific) and incubated for 16 h. The beads were then washed six times with lysis buffer before they were resuspended in Laemmli loading buffer.

Ubiquitination analysis. HCT116 cells were transfected with 2 μ g of the pcDNA.cFLIP_L expression vector, 2 μ g of the pcDNA.HA-Ubiquitin plasmid and 2 μ g of either the cIAP1, cIAP2 or TRAF2 expression constructs. 24 h after the transfection, MG132 (10 μ M) was added to the cells. 4 h later, the cells were lysed under denaturing conditions with hot lysis buffer (95° C) containing 1% SDS, 1 mM EDTA and 50 nM NaF. The lysates were then diluted (1:5) with cell lysis buffer. Cleared, diluted lysates were analysed on a 6% SDS-PAGE/Western blot for cFLIP ubiquitination.

Animal studies. Ten weeks old female CD1 nu/nu mice (Harlan) were injected with 5×10^6 cells in 200 μ l PBS. After ten days and when tumours were palpable the animals were intraperitoneally

injected with 5FU (150 mg/kg) once a week over 4 weeks. The growth of the tumours was followed over 45 days. The tumour volume was calculated using three different diameters and the formula: $\pi/6*(d1*d2*d3)$. The animal studies were performed according to national laws and were covered by a license.

Histological analyses. Tumour samples taken during necropsy were fixed in 10% neutral-buffered formalin, paraffin embedded and 4- μ m sections were stained with hematoxylin and eosin (H&E).

RNA isolation and RNA-Seq. Cells were treated with 5FU for 24 h. Total RNA was isolated using TRIZOL (Life Technologies). cDNA library preparation and sequencing was performed on an Illumina HiSeq™ 2500 by GATC Biotech. Sequence data quality control was evaluated using the FastQC program on the Galaxy platform (<http://galaxyproject.org/>). Reads were aligned to the UCSC hg19 human reference genome using Tophat2. Cufflinks was used to reconstruct the transcriptome and differentially expressed genes were identified with Cuffdiff. All analyses were performed using the Galaxy platform. Genes that were found to be upregulated in response to 24 h 5FU treatment were compared to predicted functional partners of caspase-8 (Supplementary File S8).

Statistical analysis. Experimental values are expressed as mean value \pm standard error (SEM). For significance analyses, analysis of variance (ANOVA) between groups was used.

Author contributions

AM, LD, SJ, YM, LH, SMA performed experiments; AM and RMZ conceived and designed this study; analysed and interpreted data; wrote the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare to have no conflict of interest.

Acknowledgments

We thank Greg Brooke for helpful discussions and Jigyasa Arora, Alex Menzies, Alice Godden, Rui Yu, Chirlei Klein for technical assistance and John Norton for support with the RNA-Seq experiment. RMZ was supported by an Emmy-Noether grant (ZW60/2), a Marie-Curie Excellence grant (MIST) and an RTN grant (ApopTrain).

References

1. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. *NatRevCancer* 2005; **5**: 231-237.
2. Green DR, Evan GI. A matter of life and death. *Cancer Cell* 2002; **1**: 19-30.
3. Schneider P, Tschopp J. Apoptosis induced by death receptors. *PharmActa Helv* 2000; **74**: 281-286.
4. Fulda S, Debatin KM. Targeting apoptosis pathways in cancer therapy. *CurrCancer Drug Targets* 2004; **4**: 569-576.
5. Bratton SB, MacFarlane M, Cain K, Cohen GM. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. *Exp Cell Res* 2000; **256**: 27-33.
6. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, *et al.* Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. *Nature* 2002; **419**: 634-637.
7. Tu S, McStay GP, Boucher LM, Mak T, Beere HM, Green DR. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. *Nat Cell Biol* 2006; **8**: 72-77.
8. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. *Blood* 1999; **93**: 3053-3063.
9. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. *Science* 2002; **297**: 1352-1354.
10. Sohn D, Schulze-Osthoff K, Janicke RU. Caspase-8 can be activated by interchain proteolysis without receptor-triggered dimerization during drug-induced apoptosis. *JBiolChem* 2005; **280**: 5267-5273.

11. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, *et al.* Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. *Cancer Cell* 2007; **12**: 445-456.
12. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, *et al.* IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell* 2007; **131**: 669-681.
13. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, *et al.* IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. *Cell* 2007; **131**: 682-693.
14. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, *et al.* The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. *Mol Cell* 2011; **43**: 432-448.
15. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, *et al.* cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. *Mol Cell* 2011; **43**: 449-463.
16. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. *Cell* 2011; **145**: 92-103.
17. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. *J Biol Chem* 1999; **274**: 5053-5060.
18. Tepper AD, de Vries E, van Blitterswijk WJ, Borst J. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. *J Clin Invest* 1999; **103**: 971-978.
19. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Mol Cell* 2010; **40**: 179-204.
20. Ando K, Kernan JL, Liu PH, Sanda T, Logette E, Tschopp J, *et al.* PIDD death-domain phosphorylation by ATM controls prodeath versus prosurvival PIDDosome signaling. *Mol Cell* 2012; **47**: 681-693.

21. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, *et al.* Disruption of p53 in human cancer cells alters the responses to therapeutic agents. *JClinInvest* 1999; **104**: 263-269.
22. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, *et al.* Differential requirement for caspase 9 in apoptotic pathways in vivo. *Cell* 1998; **94**: 339-352.
23. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, *et al.* Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. *Cell* 1998; **94**: 325-337.
24. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. *NatMed* 1996; **2**: 574-577.
25. Olsson M, Vakifahmetoglu H, Abruzzo PM, Hogstrand K, Grandien A, Zhivotovsky B. DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis. *Oncogene* 2009; **28**: 1949-1959.
26. Gonzalez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, *et al.* TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. *Mol Cell* 2012; **48**: 888-899.
27. Matsuda I, Matsuo K, Matsushita Y, Haruna Y, Niwa M, Kataoka T. The C-terminal domain of the long form of cellular FLICE-inhibitory protein (c-FLIPL) inhibits the interaction of the caspase 8 prodomain with the receptor-interacting protein 1 (RIP1) death domain and regulates caspase 8-dependent nuclear factor kappaB (NF-kappaB) activation. *J Biol Chem* 2014; **289**: 3876-3887.
28. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. *Mol Cell Biol* 2004; **24**: 2627-2636.
29. Suzanne M, Steller H. Shaping organisms with apoptosis. *Cell Death Differ* 2013; **20**: 669-675.
30. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. *Gut* 2005; **54**: 1024-1033.

31. Kang PM, Izumo S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. *Trends Mol Med* 2003; **9**: 177-182.
32. Perez-Garijo A, Fuchs Y, Steller H. Apoptotic cells can induce non-autonomous apoptosis through the TNF pathway. *Elife* 2013; **2**: e01004.
33. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. *EMBO J* 2002; **21**: 4520-4530.
34. Eckhart L, Ballaun C, Hermann M, VandeBerg JL, Sipos W, Uthman A, *et al.* Identification of novel mammalian caspases reveals an important role of gene loss in shaping the human caspase repertoire. *Mol Biol Evol* 2008; **25**: 831-841.
35. Janicke RU, Sohn D, Totzke G, Schulze-Osthoff K. Caspase-10 in mouse or not? *Science* 2006; **312**: 1874.
36. Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, *et al.* cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. *J Clin Invest* 2006; **116**: 174-181.
37. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. *Nature* 2002; **416**: 345-347.
38. Kamitani T, Kito K, Nguyen HP, Yeh ET. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. *J Biol Chem* 1997; **272**: 28557-28562.
39. Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, *et al.* Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells. *Stem Cells* 2010; **28**: 2109-2120.
40. Wagner KW, Engels IH, Deveraux QL. Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. *JBiolChem* 2004; **279**: 35047-35052.
41. Song JH, Bellail A, Tse MC, Yong VW, Hao C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. *J Neurosci* 2006; **26**: 3299-3308.

42. Hauer J, Puschner S, Ramakrishnan P, Simon U, Bongers M, Federle C, *et al.* TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. *Proc Natl Acad Sci U S A* 2005; **102**: 2874-2879.
43. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. *Science* 2002; **19**; **296**: 550-553.
44. Mohr A, Buneker C, Gough RP, Zwacka RM. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. *Oncogene* 2008; **27**: 763-774.
45. Ariumi Y, Turelli P, Masutani M, Trono D. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. *J Virol* 2005; **79**: 2973-2978.
46. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 2013; **8**: 2281-2308.
47. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, *et al.* Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. *J Cell Mol Med* 2008; **12**: 2628-2643.
48. Zwacka RM, Stark L, Dunlop MG. NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells. *J Gene Med* 2000; **2**: 334-343.
49. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J Immunol Methods* 1991; **139**: 271-279.
50. Stahnke K, Mohr A, Liu J, Meyer LH, Karawajew L, Debatin KM. Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis. *Apoptosis* 2004; **9**: 457-465.
51. Feig C, Tchikov V, Schutze S, Peter ME. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. *EMBO J* 2007; **26**: 221-231.

52. Mohr A, Zwacka RM. In situ trapping of initiator caspases reveals intermediate surprises. *Cell Biol Int* 2007; **31**: 526-530.

Figure Legends

Figure 1. 5FU-induced apoptosis is mediated by a caspase-9- and RIPoptosome-independent process that is initiated by caspase-8.

- a. Experimental strategy to identify compounds that act solely through potentially novel apoptosis mechanisms.
- b. (Top) AnnexinV/PI staining of HCT116 cells treated with 5FU. (Lower) Caspase-dependent apoptosis induction was assessed using zVAD in connection with DNA hypodiploidy assay. Representative results are shown.
- c. (Left) Western blot against caspase-8 with lysates from HCT116 and C8 KO cells. (Right) Apoptosis was measured in response to 5FU in these cells. Data are plotted as mean \pm SEM (n=3).
- d. Caspase-8 activity was measured after 5FU treatment in HCT116 cells. Activity is expressed as fold-caspase-8 activation. Immunoprecipitations (IP) with a control antibody (Actin IP) served as specificity control. Data are plotted as mean \pm SEM (n \geq 3).
- e. Western blots of agarose-streptavidin precipitates from 5FU/bVAD-treated cells were probed with caspase-8, -9 and -2 antibodies.
- f. Xenografts from HCT.shC8 and HCT.shctrl cells were treated with 5FU. End point tumour volumes are depicted in relation to starting volumes (set to 100) [animal numbers/group: n=6/shctrl, n=3/shC8].

Figure 2. Caspase-8 activation is p53- and death receptor-independent.

- a.** HCT116 and HCTp53^{-/-} (p53^{-/-}) cells were treated with 5FU for 24, 48 and 72 h before apoptosis was measured. Data are plotted as mean \pm SEM (n \geq 3).
- b.** Caspase-8 activity following 5FU treatment was measured in HCT116 and p53^{-/-} cells. Data are plotted as mean \pm SEM (n=4).
- c.** Caspase-8 was silenced in p53^{-/-} cells (shC8) and apoptosis measured 72 h post-treatment. Control knock-down cells (shctrl) were used for comparison. Data are plotted as mean \pm SEM (n=3).
- d.** MMP measurements in HCT116 and p53^{-/-} cells before (-) and after (+) 5FU treatment. Data are plotted as mean \pm SEM (n=3).
- e.** Apoptosis and changes in MMP after 5FU treatment were measured in stable Bid-silenced HCT116 cells (shBid). Data are plotted as mean \pm SEM (n=3).
- f.** Caspase-8 activity following 5FU treatment was measured in HCT.shBid cells. Data are plotted as mean \pm SEM (n=4).
- g.** XIAP was silenced (Ad.shXIAP) in HCT.shctrl and HCT.shBid cells and apoptosis measured after 5FU treatment. Data are plotted as mean \pm SEM (n=3). Controls were shEGFP (Ad.shEGFP) double knock-downs.
- h.** HCT116 cells were silenced for p53 and XIAP (Ad.shp53 and Ad.shXIAP) and apoptosis measured following 5FU treatment. Ad.shEGFP and Ad.shsc served as double knock-down control. Data are plotted as mean \pm SEM (n \geq 3).

Figure 3. Caspase-10 is upregulated in response to 5FU and is part of a FADD and caspase-8 containing complex.

- a. Venn diagram of genes upregulated by 5FU and a group of predicted caspase-8-interacting factors resulting in a union containing five genes.
- b. Western blot for the identified factors after 5FU treatment.
- c. p53^{-/-} cells were treated with 5FU and analysed for caspase-10 and cIAP2 by Western blot at the indicated time points.
- d. Apoptosis levels following overexpression of caspase-10 and cIAP2 in HCT.shctrl cells, and in addition of caspase-10 in HCT.shC8 cells. EGFP overexpression was used as control. Data are plotted as mean \pm SEM (n \geq 3).
- e. Caspase-8 IP from HCT116 cells treated with 5FU. Complex formation was assessed by probing the caspase-8 precipitates for the presence of FADD and caspase-10 by Western blot. The panel on the left shows the input controls.
- f. Caspase-8 IP from HCT116 cells overexpressing caspase-10. Complex formation was assessed by probing the caspase-8 precipitates for the presence of FADD and caspase-10 by Western blot. Input controls are on the left.
- g. FADD was knocked down in HCT116 and HT-29 cells (shFADD) and apoptosis was measured. HT-29.shFADD cells were treated with 200 μ M and 400 μ M 5FU. Data are plotted as mean \pm SEM (n=3).
- h. Caspase-8 activity following 5FU treatment was measured in HCT.shFADD cells. Data are plotted as mean \pm SEM (n=3).
- i. Caspase-10 silenced HCT116 cells (shC10) were treated with 5FU and analysed for apoptosis. Data are plotted as mean \pm SEM (n=7).

Figure 4. Lack of Caspase-10 leads to TNF- α production in response to 5FU and FADD-independent apoptosis.

- a. (Left) Caspase-8 activity was measured in response to 5FU in HCT.shC10 cells. (Right) Double knock-down clones, HCT.shC10.shctrl, HCT.shC10.shC8 and HCT.shC10.shFADD were tested for apoptosis in response to 5FU. Data are plotted as mean \pm SEM ($n \geq 3$).
- b. 5FU-induced apoptosis was measured in HCT.shC10 cells in the presence of TNF- α and TNF-R1 blocking antibodies. IgG1 and IgG2a antibodies were used as isotype controls, respectively. Data are plotted as mean \pm SEM ($n \geq 3$).
- c. TNF- α was measured in supernatants of 5FU-treated HCT.shC10 cells. Data are plotted as mean \pm SEM ($n=3$).
- d. HCT.shC10 cells after 5FU treatment were analysed by Western blot for I κ B- α and phospho-I κ B- α .
- e. HCT.shC10 cells expressing I κ B-SR (Ad.I κ BSR) were treated with 5FU, after which TNF- α and apoptosis were measured. Ad.EGFP served as control. Data are plotted as mean \pm SEM ($n \geq 3$).
- f. HCT116 cells silenced for both caspase-10 and caspase-8 were treated with 5FU and TNF- α was measured. Data are plotted as mean \pm SEM ($n \geq 5$).
- g. Western blot for cFLIP in HCT116 and HCT.shC10 cells after 5FU treatment.
- h. EGFP, cFLIP_S, cFLIP_L, cFLIP_{p43} and cFLIP_{D376N} were expressed in HCT116 cells, and then the cells treated with 5FU before TNF- α levels were measured. Data are plotted as mean \pm SEM ($n \geq 2$).
- i. HCT.shC10 cells were silenced for cFLIP (Ad.shFLIP). TNF- α in cell culture supernatants was then determined after 5FU stimulation. Data are plotted as mean \pm SEM ($n=2$).

- j.** Either cFLIP_L or cFLIP_{p43} were expressed in HCT.shC8 cells. After 5FU treatment, TNF- α was measured. Data are plotted as mean \pm SEM (n \geq 3).
- k.** Precipitates from a caspase-8 IP were probed for cFLIP, FADD and caspase-8. The lysates were from HCT116 cells overexpressing cFLIP_L and treated with 5FU. Cells overexpressing EGFP were used as controls. Input controls are shown on the left.
- l.** End point tumour volumes of HCT.shC10 xenografts treated with 5FU are depicted in relation to starting volumes (set to 100). [Animal numbers/group: n=6/shctrl, n=3/shC10].

Figure 5. RIP1 and TRAF2 are dispensable for 5FU-induced apoptosis, but required for FADDosome formation.







- a.** Western blot of protein lysates of HCT.shC10 cells, treated with 5FU, probed with cIAP1 antibodies.
- b.** Apoptosis measurements after 5FU treatment of the following stable knock-down clones: HCT.shctrl, HCT.shRIP1, HCT.shC10, HCT.sC10.shctrl and HCT.shC10.shRIP1. Data are plotted as mean \pm SEM ($n \geq 3$).
- c.** (Left) HCT.shctrl, HCT.shC10 and HCT.shRIP1 cells were treated with 5FU and the resulting protein lysates immuno-blotted and probed with I κ B- α and cIAP1 antibodies. (Right) TNF- α was measured in HCT.shRIP1 cells treated with 5FU. Data are plotted as mean \pm SEM ($n \geq 3$).
- d.** Caspase-8 IP in 5FU-treated HCT116 cells. Resulting precipitates were analysed by Western blot for RIP1, TRAF2 and caspase-8. Input controls are shown on the left.
- e.** (Left) Apoptosis measurements in HCT.shTRAF2 cells following 5FU treatment. (Right) TNF- α levels were measured in HCT.shTRAF2 cells treated with 5FU. Data are plotted as mean \pm SEM ($n \geq 3$).
- f.** EGFP, Δ RING-TRAF2 and TRAF2 were overexpressed in HCT116 cells and 24 h later the resulting protein extracts tested by Western blot for cFLIP.
- g.** Degradation of cFLIP was analysed in cells overexpressing EGFP, Δ RING-TRAF2 or TRAF2 following 5FU treatment. Δ RING-TRAF2 and TRAF2 expression is also shown.


Figure 6. ATR is essential for caspase-10 upregulation and FADDosome formation.

- a.** Western blot analysing ATR and ATM phosphorylation in HCT116 cells treated with 5FU for 8 h.
- b.** Apoptosis measurements in HCT116 cells treated with 5FU and a 5FU/ATR inhibitor combination, as well as HCT.shATR cells treated with 5FU. Data are plotted as mean \pm SEM ($n \geq 3$).
- c.** TNF- α measurements in HCT116 cells treated with 5FU and a 5FU/ATR inhibitor combination, as well as HCT.shATR cells treated with 5FU. Untreated HCT.shATR (u) are shown as controls. Data are plotted as mean \pm SEM ($n \geq 4$).
- d.** Western blots for caspase-10, phosphorylated Chk1, Chk1 and p53 in HCT116 cells treated with an ATR inhibitor (left) and HCT.shATR cells (right) treated with 5FU.

Figure 7. Model of cancer cell fate decisions following treatment.

- a.** Cell-autonomous cell death (FADDosome) as triggered by DNA single-strand breaks denoted by the 'red star'.
- b.** Communal cell death (FLIPosome) activated by incorporation of 5FU nucleotides into DNA/RNA or other damage types/repair mechanisms (symbolised by green DNA part).

















Fig. 3





Fig. 4










Fig. 6

a



b

